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Supplemental Figure 1. Lysosomal degradation of acetylated tau. (a) Immunoblot for the indicated 
antibodies of homogenates of brains from wild-type (WT) and tau-null (TauKO) mice. Ac: acetylated. n=3 
mice per genotype. (b) Immunoblot for the indicated antibodies of mouse brain slices incubated with the 
indicated inhibitors for 4h. n=3 mice. (c) Immunoblot for Atg7 of the indicated brain regions from wild-type 
(WT) and Atg7 knock-out (ATG7KO). n= 3 mice per genotype. (d) Changes of tau levels in brain slices from 
WT and ATG7KO cortex (left) [Two-way ANOVA Degradation pathway effect: F(2,30)=5.014, p=0.0132] or 
midbrain (right) [Two-way ANOVA Degradation pathway effect: F(2,42)=2.7, p=0.0785] incubated as in (b), n 
= 9 (cortex) and 13 (midbrain) slices for WT and 3 slices for ATG7 from 3 different mice. Representative 
immunoblots are shown in Fig. 1b. (e) Immunoblot for the indicated antibodies of mouse embryonic 
fibroblasts (MEFs) and Neuro-2a (N2a) cells transfected with unmodified FLAG-wild-type Tau (WT) or 
acetylation-mimetic FLAG-K274,281Q tau (KQ). n=3 independent experiments. (f) MEF cells transfected with 
WT or KO tau and then treated with NH4Cl and leupeptin (N/L), 3-methyladenine (3MA) or MG132 1µM for 
4h or left untreated (-). Bottom: Quantification of tau levels under the different treatments. [Two-way ANOVA 
Degradation pathway effect: F(2,24)=6.552, p=0.0054], n=9 (or None and N/L) and 6 (for 3-MA and MG-132) 
independent experiments (cell plating, treatments and cell collection performed on different days for each 
experiment). For samples run in different blots, a common lane of the same sample on each side was run 
in all of them and used for normalization purposes. Controls of inhibitors’ efficiency are shown in (g). (h) 
Immunoblot for the indicated antibodies in Neuro-2a (N2a) cells transfected with WT or KQ tau. n=3 
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independent experiments. (i) Additional characterization of the autophagosomes (APG) and autolysosomes 
(AUT) used in the study presented in main Figure 1h,i. A second antibody for LC3 that preferentially 
recognized LC3-II was used. n=3 mice. All values are mean+s.e.m. Differences were significant with 
untreated (- or None) for *p<0.05. For clarity purposes, only relevant statistical comparisons are presented. 
Uncropped blots are shown in Supplemental Figure 8. Source data are provided as a Source Data file. 
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Supplemental Figure 2. Immunohistochemistry for acetylated tau in mouse brain sections. (a) 
Immunoblot for LAMP2A of the indicated brain regions from wild-type (WT) and L2A knock-out (L2AKO). 
n=3 mice per genotype. (b) Immunohistochemistry staining for acetylated tau of brain sections from 
PS19/LG301 (positive control), wild-type (WT) and tau knock out (negative control) mice. n=3 mice per 
genotype. Scale bar: 100µm. (c) Characterization of the CMA active (+) and inactive (-) lysosomes isolated 
from brains of WT and L2AKO mice and used for the analysis of associated tau proteins shown in Fig. 2b. 
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n=3 mice per genotype. (d) Immunofluorescence for LAMP1 in hippocampus of WT and L2AKO mice at 
6months of age. Left: Representative images. Insets show higher magnification images. Nuclei are 
highlighted with DAPI. Scale bar: 20µm. Right: quantification of the number of puncta per cell shown as the 
cumulative distribution for individual cells (10 cells per animal per genotype) and mean per animal as inset. 
No significant (n.s.) statistical differences were detected between both genotypes using two-tailed t-tests. 
(e) Characterization of the lysins acetylated in the recombinant protein with antibodies specific for the 
residues. The lysine residues recognized for each antibody are annotated in the figure. The antibody 
against K-274 was not used in the in vitro assays with the recombinant protein as it presented some cross-
reactivity with the control non-acetylated tau. n=3 independent experiments. (f) Incubation of disrupted 
lysosomes with recombinant tau in the presence of the indicated protease inhibitors (PI: cocktail of serine, 
cysteine and aspartic protease inhibitors; MG-132: proteasome inhibitor). Left: representative immunoblot. 
Right: densitometric quantification of 3 independent experiments. No significant (n.s.) statistical differences 
were detected between control and MG132 samples using two-tailed t-tests. Values are mean+s.e.m. 
Uncropped blots are shown in Supplemental Figure 8. Source data are provided as a Source Data file. 
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Supplemental Figure 3. Impact of acetylated tau and pH changes on CMA dynamics. (a) mRNA levels 
of human tau in N2a cells transfected with an empty vector (PGK) or plasmids coding for unmodified wild-
type Tau (WT) or acetylation-mimetic K274,281Q tau (KQ) tau. [One-way ANOVA F(2,6)=16.87, p=0.0034] n=3 
independent experiments.  (b) Immunoblot for LAMP-2A of blue-native electrophoresis of lysosomes 
incubated alone or with in vitro acetylated tau (Ac-tau) and supplemented with the indicated concentrations 
of the hsc70 activator (JG48). n=3 independent experiments. (c) Full curves of tau or K280Q tau binding 
assay to immobilized hsc70 determined by ELISA at different pH. n= 6 (in 2 independent experiments). (d) 
ATPase competency assay for hsc70 at different pH determined by absorbance to determine phosphate 
concentration; n= 6 (in 2 independent experiments). in triplicates. All values are mean+s.e.m. (e) 
Percentage of broken lysosomes after the indicated treatments calculated from the activity of 
hexosaminidase detected outside lysosomes relative to that in lysosomes. n= 3. No significant (n.s.) 
statistical differences were detected across conditions using One-way ANOVA. (f) Immunoblots of 
lysosomes from starved rat livers, pre-treated or not with protease inhibitors (PI) and/or NH4Cl 20mM or 
Bafilomycin (20 M) for 10 minutes at 4ºC and then incubated with GAPDH. Inpt: input 1 g GAPDH. Right: 
Quantification of GAPDH uptake by the lysosomes shown on the right. n= 3. No significant (n.s.) statistical 
differences were detected across treatments using one-way ANOVA. Uncropped blots are shown in 
Supplemental Figure 8. Source data are provided as a Source Data file. 




Supplemental Figure 4. siVps4-mediated knock down and Isolated lysosomes proteolytic activity. 
(a) Immunoblot with the indicated antibodies of homogenate (Hom) and late endosomes (LE) isolated from 
mice brain. Dashed line indicates separation between running and stacking gel. The same homogenate 
and LE fractions were loaded in triplicate in a gel and strips of the membrane were separately incubated 
with each of the antibodies to allow for comparison among antibodies. n=3 mice. (b) Immunoblots for the 
indicated proteins of lysate and media from control and siRNA-mediated Vps4 knock-down (VPS4KD) HEK 
cells transfected with FLAG-wild-type tau (WT tau). Top: representative immunoblot. Bottom: quantification 
of the amount of tau [Two tailed t-test t4=6.708, p=0.0026] (left), percentage of tau degradation per hour 
[Two tailed t-test t4=14.48, p=0.0001] (middle) and levels of extracellular tau [Two tailed t-test t4=1.789, 
p=0.1481] (right) relative to those in control cells. n= 3 independent experiments. Values are mean+s.e.m. 
(c) Immunoblots for the indicated proteins to confirm the knock-down in the cells used for the experiments 
in main Figure 4g. n=3 independent experiments. (d,e) Analysis of macroautophagy activity in N2a cells 
control (CTR) or upon knock-down of Vps4 (VPS4KD). (d) Macroautophagy flux measured upon expression 
of the mCherry-GFP-LC3 tandem reporter. Left: Representative images of merged channels. Nuclei are 
highlighted with DAPI. Right: Quantification of number of autophagosomes [Two tailed t-test t35=2.253, 
p=0.0307, n=15 (control) and 22 (VPS4KD) cells] (APG, yellow puncta) and autolysosomes (AUTL, red 
only puncta) [Two tailed t-test t35=2.385, p=0.0226, n=15 (control) and 22 (VPS4KD) cells]. (e) Proteolysis 
of long-lived proteins in WT and VPS4KD cells radiolabelled with 3H-leucine for 48h and maintained without 
additions or in the presence of 3-methyladenine (3MA) to inhibit macroautophagy. Protein degradation was 
measured as the amount of acid-precipitable radioactivity (amino acids and small peptides) released into 
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the media and values are expressed as percentage of total radiolabelled protein at the beginning of the 
chase. Left: Total protein degradation. Right: Percentage of total proteolysis sensitive to 3MA. n = 3 different 
experiments with triplicate wells. All values are mean+s.e.m. Differences with CTR were significant for 
*p<0.05, **p<0.01. For clarity purposes, only relevant statistical comparisons are presented. Uncropped 
blots are shown in Supplemental Figure 8. Source data are provided as a Source Data file. 
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Supplemental Figure 5. Isolation of autophagic compartments from human brain. (a) Immunoblot for 
the indicated forms of tau in homogenates of brains from control and Alzheimer’s disease (AD) patients. 
n=4 brains from each diagnosis are shown. (b-e) Immunoblot for the indicated proteins of homogenates 
(Hom), cytosol (Cyt) and two populations of lysosomes (Lys) with different CMA activity (CMA+ and CMA-
) (b), or autophagic vacuoles (AV) (c, e) or late endosomes (LE) (d, e) isolated from the frontal area of 
brains from patients with Alzheimer’s Disease (AD, n=6) and non-neurological patients of matching age 
(Control, n=7). (f) Immunoblot for the indicated proteins in total lysosomes and lysosomal matrix (L. Matrix) 
from AD patients and controls (Ctr). n=3 samples (1 per brain) per condition. (g) Immunoblot for oligomeric 
(T22 antibody) and phosphorylated (PHF1 antibody) human tau in LE isolated from the frontal area of brains 
from CTR or AD patients. Ponceau staining as control of loading of equal protein amounts per lane. Bottom: 
quantification of oligomeric (left) and phosphorylated (right) tau in CTR and AD patients. n= 2 non-
neurological controls and 4 AD patients. Individual values and mean+s.e.m. are shown. No significant (n.s.) 
statistical differences were detected between both genotypes using two-tailed t-tests. Uncropped blots are 
shown in Supplemental Figure 8. Source data are provided as a Source Data file. 




Supplemental Figure 6. CMA deficiency and Tau spreading. (a) Co-localization of human tau (huTau) 
with glia markers: microglia (Iba1) and astrocytes (GFAP) between WT and L2AKO mice at 8 weeks after 
injection. Right: quantification of mean huTau intensity in different brain cell populations. [Two way ANOVA 
Cell-type effect F2,18=235.8, p<0.0001; Genotype effect F1,18=16.26, p=0.0008], n= 4 per genotype. (b) 
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mRNA levels of human tau from brains of WT and L2AKO mice at 2 weeks after surgery [Two-tailed t-test 
t4=0.2463, p=0.8176]. (c) Representative images of GFP and huTau immunofluorescence staining in CA1 
and CA3 of the hippocampus between WT and L2AKO mice at 2 and 4 weeks after surgery. White arrows 
highlight recipient cells. Bottom: Number of donor cells overtime between WT and L2AKO mice; [Two-way 
ANOVA Cell-type effect F2,14=5.510, p=0.0172] n= 3 mice per genotype for 2 and 4 weeks and 4 mice per 
genotype for 8 weeks). (d) Representative images of GFP and acetylated tau (K174) immunostainings in 
CA1 and CA3 of the hippocampus of WT and L2AKO mice at 8 weeks post-injection. (e) Quantification of 
GFP (left) and acetylated tau (Ac-Tau) (right) intensity in donor cells of WT and L2AKO mice at 8 weeks 
post-surgery [Two-tailed t-test t6=4.5522, p=0.0039]; n=4 per genotype. (f) Quantification of acetylated tau 
(Ac-Tau) intensity in recipient cells of WT and L2AKO mice at 8 weeks post-surgery [Two-tailed t-test 
t6=2.6239, p=0.0393]; n= 4 per genotype. Data are mean±s.e.m. Differences with WT mice were significant 
for **p<0.005, *** p<0.0005. Source data are provided as a Source Data file. 
  








Supplementary Fig. 7. Uncropped gels from Main Figures 1-5. Dotted red boxes mark 
cropped areas shown in the main figure of the membrane blotted for the protein indicated 
on the left.  Ponceau staining is shown in those instances in which total protein per line 
was used for normalization in the densitometric analysis. 
  





Supplementary Fig. 8. Uncropped gels from Supplemental Figures 1-6. Dotted red 
boxes mark cropped areas shown in the supplemental figure of the membrane blotted for 
the protein indicated on the left.  Ponceau staining is shown in those instances in which 
total protein per line was used for normalization in the densitometric analysis. 
  




Supplementary Table 1. qRT-PCR primers used in the study 
 
 
Target Forward primer Reverse primer 





B2M 5’-CAC-TGA-ATT-CAC-CCC-CAC-TGA-3’ 5’-TCA-CAT-GTC-TCG-ATC-CCA-GT-3’ 
 
 
 
 
 
